8-KOther Events

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Mar 17, 2022)

Filed March 17, 2022For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) announced on March 17, 2022, that it has filed patent infringement lawsuits against Pfizer, Inc. and Moderna, Inc. regarding their respective mRNA COVID-19 vaccines. The lawsuits specifically allege infringement of U.S. Patent No. 11,246,933 (the '933 Patent), which covers Alnylam's proprietary biodegradable cationic lipids. These lipids are described as foundational to the success of mRNA vaccines, suggesting a critical role in the technology utilized by these widely distributed vaccines. The company is seeking monetary damages for the alleged unlicensed use of its patented lipids, aiming for compensation that reflects a reasonable royalty for the infringement. Importantly, Alnylam is not seeking to halt the production or sale of Pfizer's and Moderna's vaccines through injunctive relief. This legal action highlights the value Alnylam places on its intellectual property in the rapidly growing mRNA therapeutics space and could have significant financial implications if successful.

Key Highlights

  • 1Alnylam Pharmaceuticals has filed patent infringement lawsuits against Pfizer and Moderna.
  • 2The lawsuits concern the manufacture and sale of Pfizer's and Moderna's mRNA COVID-19 vaccines.
  • 3The core of the litigation is the alleged infringement of U.S. Patent No. 11,246,933 ('933 Patent').
  • 4The '933 Patent covers Alnylam's proprietary biodegradable cationic lipids, described as foundational to mRNA vaccine success.
  • 5Alnylam is seeking monetary damages, including a reasonable royalty, for the alleged infringement.
  • 6The company is NOT seeking injunctive relief, meaning it is not asking to stop the sale or production of the vaccines.

Frequently Asked Questions

Alnylam is suing Pfizer and Moderna for patent infringement. They allege that the companies' mRNA COVID-19 vaccines infringe on U.S. Patent No. 11,246,933, which covers Alnylam's patented biodegradable cationic lipids essential for these vaccines.

The '933 Patent is related to Alnylam's proprietary biodegradable cationic lipids. These are a key component described as foundational to the success and effectiveness of mRNA COVID-19 vaccines.

No, Alnylam has explicitly stated that they are not seeking injunctive relief in these lawsuits. This means they are not asking the court to halt the production or sale of Pfizer's or Moderna's mRNA COVID-19 vaccines.

Alnylam is seeking monetary damages adequate to compensate for the infringement. This includes compensation for the unlicensed use of their patented lipids, calculated at no less than a reasonable royalty, plus interest and costs.